Synthesis and in vitro anticancer evaluation of some novel hexahydroquinoline derivatives having a benzenesulfonamide moiety

European Journal of Medicinal Chemistry

Volumn 46, Issue 1, 2011, Pages 201-207

  Al Said, Mansour S ^a   Ghorab, Mostafa M ^a   Al Dosari, Mohammed S ^a   Hamed, Mostafa M ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b German University in Cairo   (Egypt)

Author keywords

Anticancer; Pyrimidoquinoline; Quinoline; Sulfonamide

Indexed keywords

2 AMINO 4 (2,4 DICHLOROPHENYL) 5 OXO 1 (4 SULFAMOYLPHENYL) 1,4,5,6,7,8 HEXAHYDROQUINOLINE 3 CARBOXAMIDE; 2 AMINO 4 (2,4 DICHLOROPHENYL) 5 OXO 1 (4 SULFAMOYLPHENYL) 1,4,5,6,7,8 HEXAHYDROQUINOLINE 3 CARBOXYLIC ACID; 3 CHLORO N [3 CYANO 4 (2,4 DICHLOROPHENYL) 5 OXO 1 (4 SULFAMOYLPHENYL) 1,4,5,6,7,8 HEXAHYDROQUINOLIN 2 YL]BUTANAMIDE; 4 [2 (2 CHLOROPROPYL) 5 (2,4 DICHLOROPHENYL) 4,6 DIOXO 3,4,6,7,8,9 HEXAHYDROPYRIMIDO[4,5 B]QUINOLIN 10(5H) YL]BENZENESULFONAMIDE; 4 [2 (4 BROMOPHENYL) 5 (2,4 DICHLOROPHENYL) 4,6 DIOXO 3,4,6,7,8,9 HEXAHYDROPYRIMIDO[4,5 B]QUINOLIN 10(5H) YL]BENZENESULFONAMIDE; 4 [2 (CHLOROMETHYL) 5 (2,4 DICHLOROPHENYL) 4,6 DIOXO 3,4,6,7,8,9 HEXAHYDROPYRIMIDO[4,5 B]QUINOLIN 10(5H) YL]BENZENESULFONAMIDE; 4 [2 AMINO 3 CYANO4 (2,4 DICHLOROPHENYL) 5 OXO 5,6,7,8 TETRAHYDROQUINOLIN 1(4H) YL]BENZENESULFONAMIDE; 4 [2 CYCLOPROPYL 5 (2,4 DICHLOROPHENYL) 4,6 DIOXO 3,4,6,7,8,9 HEXAHYDROPYRIMIDO[4,5 B]QUINOLIN 10(5H) YL]BENZENESULFONAMIDE; 4 [3 CYANO 4 (2,4 DICHLOROPHENYL) 2 (2,4 DINITROBENZYLIDENEAMINO) 5 OXO 5,6,7,8 TETRAHYDROQUINOLIN 1(4H) YL]BENZENESULFONAMIDE; 4 [3 CYANO 4 (2,4 DICHLOROPHENYL) 2 [3 [4 (DIMETHYLAMINO)PHENYL]ALLYLIDENEAMINO] 5 OXO 5,6,7,8 TETRAHYDROQUINOLIN 1(4H) YL]BENZENESULFONAMIDE; 4 [3 CYANO 4 (2,4 DICHLOROPHENYL) 2 [4 (DIMETHYLAMINO)BENZYLIDENEAMINO] 5 OXO 5,6,7,8 TETRAHYDROQUINOLIN 1(4H) YL]BENZENESULFONAMIDE; 4 [5 (2,4 DICHLOROPHENYL) 2 METHYL 6 OXO 4 THIOXO 3,4,6,7,8,9 HEXAHYDROPYRIMIDO[4,5 B]QUINOLIN 10(5H) YL]BENZENESULFONAMIDE; 4 [5 (2,4 DICHLOROPHENYL) 4,6 DIOXO 2 4 TOLYL 3,4,6,7,8,9 HEXAHYDROPYRIMIDO[4,5 B]QUINOLIN 10(5H) YL]BENZENESULFONAMIDE; 4 [5 (2,4 DICHLOROPHENYL) 4,6 DIOXO 2 PHENYL 3,4,6,7,8,9 HEXAHYDROPYRIMIDO[4,5 B]QUINOLIN 10(5H) YL]BENZENESULFONAMIDE; ANTINEOPLASTIC AGENT; BENZENESULFONAMIDE DERIVATIVE; DOXORUBICIN; ETHYL N [3 CYANO 4 (2,4 DICHLOROPHENYL) 5 OXO 1 (4 SULFAMOYLPHENYL) 1,4,5,6,7,8 HEXAHYDROQUINOLIN 2 YL]FORMIMIDATE; N (3 CYANO 4 (2,4 DICHLOROPHENYL) 5 OXO 1 (4 SULFAMOYLPHENYL) 1,4,5,6,7,8 HEXAHYDROQUINOLIN 2 YL] 3 OXO BUTANAMIDE; N [3 CYANO 4 (2,4 DICHLOROPHENYL) 5 OXO 1 (4 SULFAMOYLPHENYL 1,4,5,6,7,8 HEXAHYDROQUINOLIN 2 YL] 3,4,5 TRIMETHOXYBENZAMIDE; N [3 CYANO 4 (2,4 DICHLOROPHENYL) 5 OXO 1 (4 SULFAMOYLPHENYL 1,4,5,6,7,8 HEXAHYDROQUINOLIN 2 YL] 4 METHYLBENZAMIDE; N [3 CYANO 4 (2,4 DICHLOROPHENYL) 5 OXO 1 (4 SULFAMOYLPHENYL 1,4,5,6,7,8 HEXAHYDROQUINOLIN 2 YL]4 NITROBENZAMIDE; N [3 CYANO 4 (2,4 DICHLOROPHENYL) 5 OXO 1 (4 SULFAMOYLPHENYL 1,4,5,6,7,8 HEXAHYDROQUINOLIN 2 YL]BENZAMIDE; N [3 CYANO 4 (2,4 DICHLOROPHENYL) 5 OXO 1 (4 SULFAMOYLPHENYL 1,4,5,6,7,8 HEXAHYDROQUINOLIN 2 YL]CINNAMIDE; N [3 CYANO 4 (2,4 DICHLOROPHENYL) 5 OXO 1 (4 SULFAMOYLPHENYL 1,4,5,6,7,8 HEXAHYDROQUINOLIN 2 YL]CYCLOPROPANE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG BINDING SITE; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME ACTIVE SITE; FEMALE; IN VITRO STUDY; MOLECULAR MODEL; MOUSE; NONHUMAN;

ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASE II; CATALYTIC DOMAIN; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; QUINOLINES; SULFONAMIDES;

EID: 78650512902     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.11.002     Document Type: Article

References (31)

1. A.E. Boyd 3rd Diabetes 37 1988 847 850
2. J. Drews Science 287 2000 1960 1964
3. T.H. Maren Annu. Rev. Pharmacol. Toxicol. 16 1976 309 327
4. C.T. Supuran, and A. Scozzafava Expert Opin. Ther. Pat. 10 2000 575 600
5. F. Abbate, A. Casini, T. Owa, A. Scozzafava, and C.T. Supuran Bioorg. Med. Chem. Lett. 14 2004 217 223
6. Z. Huang, Z. Lin, and J. Huang Eur. J. Med. Chem. 36 2001 863 872
7. M.M. Ghorab, F.A. Ragab, and M.M. Hamed Eur. J. Med. Chem. 44 2009 4211 4217
8. M.M. Mader, C. Shih, E. Considine, A.D. Dios, C.S. Grossman, P.A. Hipskind, H.S. Lin, K.L. Lobb, B. Lopez, J.E. Lopez, L.M. Cabrejas, M.E. Richett, W.T. White, Y.Y. Cheung, Z. Huang, J.E. Reilly, and S.R. Dinn Bioorg. Med. Chem. Lett. 15 2005 617 620
9. S.A. Rostom Bioorg. Med. Chem. 14 2006 6475 6485
10. C.T. Supuran, A. Casini, A. Mastrolorenzo, and A. Scozzafava Mini-Rev. Med. Chem. 4 2004 625 632
11. A.J. Kivela, J. Kivela, J. Saarnio, and S. Parkkila World J. Gastroenterol. 11 2005 155 163
12. A. Scozzafava, T. Owa, A. Mastrolorenzo, and C.T. Supuran Curr. Med. Chem. 10 2003 925 953
13. C.T. Supuran Nat. Rev. Drug Discov. 7 2008 168 181
14. C.T. Supuran, and A. Scozzafava Bioorg. Med. Chem. 15 2007 4336 4350
15. A. Casini, A. Scozzafava, A. Mastrolorenzo, and L.T. Supuran Curr. Cancer Drug Targets 2 2002 55 75
16. S. Pastorekova, S. Parkkila, J. Pastorek, and C.T. Supuran J. Enzym. Inhib. Med. Chem. 19 2004 199 229
17. F. Saczewski, J. Slawinski, A. Kornicka, Z. Brzozowski, E. Pomarnacka, A. Innocenti, A. Scozzafava, and C.T. Supuran Bioorg. Med. Chem. Lett. 16 2006 4846 4851
18. F. Saczewski, A. Innocenti, J. Slawinski, A. Kornicka, Z. Brzozowski, E. Pomarnacka, A. Scozzafava, C. Temperini, and C.T. Supuran Bioorg. Med. Chem. 16 2008 3933 3940
19. M. Lopez, L.F. Bornaghi, A. Innocenti, D. Vullo, S.A. Charman, C.T. Supuran, and S.A. Poulsen J. Med. Chem. 53 2010 2913 2926
20. W.R. Chegwidden, and I.M. Spencer Inflammopharmacology 3 1995 231 239
21. M. Gopal, S. Shenoy, and L.S. Doddamani J. Photochem. Photobiol. B. 72 2003 69 78
22. Y.H. Kim, K.J. Shin, T.G. Lee, E. Kim, M.S. Lee, S.H. Ryu, and P.G. Suh Biochem. Pharmacol. 69 2005 1333 1341
23. J.P. Liou, Z.Y. Wu, C.C. Kuo, C.Y. Chang, P.Y. Lu, C.M. Chen, H.P. Hsieh, and J.Y. Chang J. Med. Chem. 51 2008 4351 4355
24. Y.L. Zhao, Y.L. Chen, F.S. Chang, and C.C. Tzeng Eur. J. Med. Chem. 40 2005 792 797
25. M.M. Ghorab, F.A. Ragab, E. Noaman, H.I. Heiba, and E.M. El-Hossary Arzneim. Forsch. 57 2007 795 803
26. M.M. Ghorab, F.A. Ragab, E. Noaman, H.I. Heiba, and E.M. El-Hossary Arzneim. Forsch 58 2008 35 41
27. S.I. Al-qasoumi, A.M. Al-Taweel, A.M. Alafeefy, E. Noaman, and M.M. Ghorab Eur. J. Med. Chem. 45 2010 738 744
28. M.M. Ghorab, S.M. Abdel-Gawad, and M.S. El-Gaby Farmaco 55 2000 249 255
29. G. Tacconi, G. Gatti, G. Desimoni, and V. Messori J. Prakt. Chem. 322 1980 831 834
30. Molecular Operating Environment (MOE 2007.09). Chemical Computing Group, Inc. Montreal, Quebec, Canada. In, Molecular Operating Environment (MOE 2007.09). Chemical Computing Group, Inc. Montreal, Quebec, Canada.
31. D. Brusick J.F. Douglas, Carcinogenesis and Mutagenesis Testing 1984 Human Press Inc. Clifton, New Jersey 265 276